Skip to main content
. 2019 Apr 3;2019:1240537. doi: 10.1155/2019/1240537

Table 2.

Ocular MMP-9 status by study group.

Preservative-free treatment (tafluprost) (n=30) BAK-containing treatment (latanoprost) (n=30) Untreated (control) (n=30)
MMP-9 (>40 ng/mL)
Negative 25 eyes (83.3%) 16 eyes (53.3%) 25 eyes (83.3%)
Positive 5 eyes (16.7%,‡) 14 eyes (46.7%) 5 eyes (16.7%,‡)

Level of significance: p < 0.05; significance of difference relative to the BAK-containing treatment (latanoprost) group.